Skip to main
ACON
ACON logo

Aclarion Inc (ACON) Stock Forecast & Price Target

Aclarion Inc (ACON) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aclarion Inc. has demonstrated impressive year-over-year revenue growth, reporting a 31% increase in Q3 FY25 revenue to $18,942, significantly driven by an 89% rise in Nociscan report volumes. The company's strategic investments in sales and marketing, which increased by 172% year-over-year, highlight a commitment to enhancing market penetration and supporting its upcoming CLARITY trial, thereby setting the stage for long-term growth. Furthermore, Aclarion is experiencing momentum through new commercial agreements with reputable medical institutions, alongside favorable coverage decisions in the UK, suggesting a robust upward trajectory for the adoption of its Nociscan platform.

Bears say

Aclarion Inc. faces significant financial risks stemming from slow adoption of its Nociscan product by both surgeons and payers, coupled with escalating marketing and administrative expenses, which could hinder revenue growth. The company's financial outlook has been negatively adjusted multiple times, with the FY25 earnings per share (EPS) estimates lowered to $(15.13) and $(15.08), reflecting increased operational costs that exceed prior estimates. Furthermore, potential challenges such as balance sheet and liquidity risks, regulatory approval failures, and difficulties in securing reimbursement underscore the ongoing uncertainty surrounding Aclarion's ability to commercialize its product effectively.

Aclarion Inc (ACON) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclarion Inc (ACON) Forecast

Analysts have given Aclarion Inc (ACON) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aclarion Inc (ACON) has a Strong Buy consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclarion Inc (ACON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.